drugset / Trial / NCT04950933

The Treatment of Amyotrophic Lateral Sclerosis With Huollingshengji Granules

NCT04950933

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study intends to evaluate the efficacy and safety of Dong Lingsheng Ji Granule in the treatment of amyotrophic lateral sclerosis (spleen deficiency, kidney-yang deficiency syndrome) in comparison with riluzole, so as to provide data support for marketing application or subsequent clinical research design.

Timeline

Start
2020-06-01
Primary completion
2021-12-31
Completion
2022-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Huolingshengji Granules Unknown 1 unknown Oral
Comparator Riluzole Small molecule 1 unknown Oral